Aligning Industrial Strategy with Health Access Needs
South Africa’s dependence on imported pharmaceutical products poses significant challenges to medicine security, pricing stability, and health system resilience. The COVID-19 pandemic and recurring global supply chain disruptions have exposed the vulnerabilities of over-reliance on international suppliers, particularly for essential medicines and active pharmaceutical ingredients (APIs). Strengthening domestic pharmaceutical manufacturing is not only a matter of industrial development but a critical component of achieving long-term healthcare access and supply chain sustainability.
The Current Landscape
South Africa has a relatively well established pharmaceutical market but continues to rely heavily on imports, especially for APIs and finished formulations. Despite local manufacturing capacity, over 70% of medicines on the national Essential Medicines List are sourced externally. This creates exposure to global market fluctuations, shipping delays, and foreign exchange volatility, all of which can disrupt supply and increase costs.
Furthermore, while local pharmaceutical companies contribute meaningfully to public sector supply via the government’s tender system, their capacity is often limited to final formulation and packaging, rather than end-to-end production. This partial dependency restricts industrial value retention and limits agility in responding to public health emergencies.
Industrial Strategy as a Health Imperative
Strengthening local pharmaceutical manufacturing aligns directly with national health and economic priorities. It enables greater supply chain control, reduces import dependence, and supports job creation and skills development. Importantly, it also creates the potential for regional trade and pharmaceutical export growth under frameworks like the African Continental Free Trade Area (AfCFTA).
The Department of Trade, Industry and Competition (DTIC), in collaboration with the Department of Health, has identified pharmaceuticals as a key sector for industrial policy. Initiatives such as the Industrial Policy Action Plan (IPAP) and the South African Health Products Master Plan have called for increased investment in local production capacity. However, translating these policies into sustainable manufacturing ecosystems requires coordinated investment in technology, infrastructure, regulatory support, and workforce development.
Regulatory Enablement and Market Incentives
The regulatory environment plays a pivotal role in enabling local manufacturing. Streamlining registration timelines, prioritising local producers in tenders, and introducing transparent preference scoring systems can help create a competitive edge for domestic firms.
Additionally, government procurement policy must incentivise quality, cost-competitive local products without compromising supply reliability. Mechanisms such as forward contracting, public-private manufacturing partnerships, and pooled procurement can provide predictable demand and economies of scale.
There is also scope for regional regulatory harmonisation. Aligning quality standards and product registration protocols across Southern African Development Community (SADC) countries would open larger markets to South African manufacturers and reduce duplication in regulatory submissions.
Investing in API Production and Innovation
A key gap in South Africa’s pharmaceutical supply chain is local API production. Establishing API manufacturing requires significant capital, skilled labour, and consistent demand, but is essential for medicine security. Government support, through concessional financing, tax incentives, and public-private innovation hubs, can help lower the entry barrier for API development.
At the same time, building centres of excellence in pharmaceutical sciences at academic and research institutions will support long-term innovation and product diversification. Linking industrial research with public health needs, such as developing formulations for priority diseases like HIV, TB, diabetes, and hypertension, can ensure that innovation serves both market and public interest.
The Path Forward
Reinforcing South Africa’s pharmaceutical manufacturing capacity is an urgent strategic imperative. Doing so strengthens not only medicine supply security but also supports economic development, regional integration, and public health resilience.
By aligning industrial policy with health access objectives, through regulatory support, infrastructure investment, innovation incentives, and market coordination, South Africa can reduce vulnerability to external shocks, improve self-sufficiency, and ensure sustainable access to essential medicines for all.